Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | AVPR1B | P47901 | 4/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4305547 | 0.94 | KCNH2 (0.52) | KCNH2LTA4HEPHX2AVPR1BKDM2B | |
| SCHEMBL18529059 | 0.90 | KCNH2 (0.55) | KCNH2AVPR1BSLC2A1 | |
| SCHEMBL20679525 | 0.90 | KCNH2 (0.55) | KCNH2AVPR1BSLC2A1 | |
| SCHEMBL4294484 | 0.81 | KCNH2 (0.52) | KCNH2KDM2BPDE5A | |
| SCHEMBL4298780 | 0.81 | KCNH2 (0.55) | KCNH2 | |
| SCHEMBL12046817 | 0.80 | KCNH2 (0.71) | KCNH2 | |
| SCHEMBL18544235 | 0.79 | KCNH2 (0.50) | KCNH2 | |
| SCHEMBL4303090 | 0.79 | KCNH2 (0.52) | KCNH2 | |
| SCHEMBL4303020 | 0.78 | KCNH2 (0.44) | KCNH2KDM2BPDE5A | |
| SCHEMBL4298215 | 0.77 | KCNH2 (0.53) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044077-B1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LTD (GB) | 2016-10-05 | — | — | EP | disclosed |
| US-8071592-B2 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| EP-1992628-A1 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2008-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | ETFA, NQO2, GNAQ | KCNH2 2142/4885LTA4H 2641/4885EPHX2 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.